

PAPER

Dairy augmentation of total and central fat loss in obese subjects

MB Zemel^{1*}, J Richards¹, S Mathis², A Milstead¹, L Gebhardt¹ and E Silva³

¹Department of Nutrition, The University of Tennessee, Knoxville, TN, USA; ²Childrens Hospital, Knoxville, TN, USA; and ³Bell Institute for Health and Nutrition, General Mills Inc., Golden Valley, MN, USA

BACKGROUND AND OBJECTIVE: We have previously demonstrated an antiobesity effect of dietary Ca; this is largely mediated by Ca suppression of calcitriol levels, resulting in reduced adipocyte intracellular Ca²⁺ and, consequently, a coordinated increase in lipid utilization and decrease in lipogenesis. Notably, dairy Ca is markedly more effective than other Ca sources.

DESIGN: Obese subjects were placed on balanced deficit (–500 kcal/day) diets and randomized to control (400–500 mg Ca/day; *n* = 16) or yogurt (1100 mg Ca/day; *n* = 18) treatments for 12 weeks. Dietary macronutrients and fiber were held constant at the US average.

MEASUREMENTS: Body weight, body fat and fat distribution (by dual-energy X-ray absorptiometry), blood pressure and circulating lipids were measured at baseline and after 12 weeks of intervention.

RESULTS: Fat loss was markedly increased on the yogurt diet (–4.43 ± 0.47 vs –2.75 ± 0.73 kg in yogurt and control groups; *P* < 0.005) while lean tissue loss was reduced by 31% on the yogurt diet. Trunk fat loss was augmented by 81% on the yogurt vs control diet (*P* < 0.001), and this was reflected in a markedly greater reduction in waist circumference (–3.99 ± 0.48 vs –0.58 ± 1.04 cm, *P* < 0.001). Further, the fraction of fat lost from the trunk was higher on the yogurt diet vs control (*P* < 0.005).

CONCLUSION: Isocaloric substitution of yogurt for other foods significantly augments fat loss and reduces central adiposity during energy restriction.

International Journal of Obesity advance online publication, 11 January 2005; doi:10.1038/sj.ijo.0802880

Keywords: calcium; dairy; energy restriction; fat loss; yogurt

Introduction

A substantial body of evidence has emerged over the last 3 y in support of an ‘antiobesity’ effect of dietary calcium and dairy products.^{1–7} Increasing dietary calcium in the absence of energy restriction appears to result in a repartitioning of dietary energy from adipose tissue to lean body mass, resulting in a net reduction in fat mass in both mice and humans.^{1,8} Furthermore, increasing dietary calcium intake during energy restriction resulted in a marked augmentation of body weight loss and fat loss in both mice and humans.^{3,5,6,9–11} Notably, when dairy is the source of the calcium, these effects are more pronounced, suggesting that additional components of dairy contribute to this effect. These findings are supported by epidemiological observations from NHANES III,¹ The Quebec Family Study,¹² The

Continuing Survey of Food Intake by Individuals (CSFII),¹³ the CARDIA study¹⁴ and the HERITAGE Family Study.¹⁵

We recently reported that increasing dietary calcium significantly augmented weight and fat loss secondary to a fixed level of energy restriction (a deficit of 500 kcal/day).¹¹ Increasing dietary calcium intake from ~400 to ~1200 mg/day during energy restriction resulted in 26 and 38% increases in weight and fat loss, respectively, while utilizing dairy foods rather than calcium supplements without changing energy or macronutrient intake resulted in 70 and 64% increases in weight and fat loss. Moreover, fat loss from the trunk region was markedly increased, from 19% of total fat loss on a low-calcium diet to 50 and 66% on high-calcium and high-dairy diets, respectively.¹¹

Our previous studies of the role of intracellular Ca²⁺ signaling and calcitrophic hormones in regulating human adipocyte metabolism provide a logical framework for understanding this antiobesity effect of calcium and dairy products. These mechanisms have recently been reviewed.^{3,4} In brief, the increase in calcitriol (1,25-dihydroxyvitamin D), which occurs in response to low-calcium diets, acts on adipocytes via a specific membrane vitamin D receptor to

*Correspondence: Dr MB Zemel, Department of Nutrition, The University of Tennessee, 1215 W Cumberland Ave, Room 229, Knoxville, TN 37996-1920, USA.

E-mail: mzemel@utk.edu

Received 15 July 2004; revised 29 September 2004; accepted 30 September 2004

increase Ca^{2+} influx. The resultant increase in intracellular Ca^{2+} exerts a coordinated effect on adipocyte lipid metabolism, serving to stimulate lipogenic gene expression and lipogenesis and to suppress lipolysis, thereby increasing lipid filling and adiposity. In addition, calcitriol also acts via a nuclear vitamin D receptor to suppress the expression of adipocyte uncoupling protein 2 (UCP2) expression, thereby limiting mitochondrial fatty acid transport and oxidation.¹⁶ In contrast, high-calcium diets suppress calcitriol levels, resulting in reduced lipogenic gene expression and increases in lipolysis and UCP2 expression, thereby reducing lipid filling and adiposity. As noted above, dairy products exert significantly greater effects than calcium *per se*, and this augmented effect is likely due to additional bioactive compounds, such as angiotensin converting enzyme inhibitors, which are found in dairy, as well as to the rich concentrations of branched-chain amino acids, which may act in concert with calcium to attenuate adiposity.³

Our previous prospective clinical trial utilized a mixture of milk, cheese and yogurt as dairy sources and, accordingly, it was not possible to attribute an antiobesity effect to any single dairy product. Accordingly, the present study was conducted to determine if the utilization of a single dairy product (yogurt) in a highly structured diet would result in a comparable augmentation of weight and fat loss to that observed with a mixture of dairy products.

Materials and methods

Study design

This study was designed to determine whether a fermented dairy product (yogurt) will accelerate weight and fat loss induced by caloric restriction in 38 otherwise healthy obese adults. Subjects were studied for a 2-week lead-in period to establish their current caloric requirements and provide an opportunity for baseline dietary and physiological assessment, and then randomized to the following outpatient dietary regimens for 12 weeks: (1) a control diet providing a 500 kcal/day deficit, 0–1 servings of dairy products/day and 400–500 mg calcium per day; or (2) a yogurt diet providing a 500 kcal/day deficit and containing three daily six-ounce servings of a commercial fat-free yogurt (Yoplait Light), to bring the total calcium intake from 500 to 1100 mg/day. All calcium in both diets was derived from food sources. The control diet incorporated as a placebo three daily servings of a sugar-free, calcium-free, prepackaged flavored gelatin dessert containing 10 kcal/serving.

Subjects were provided individual instruction, counseling and assessment from the study dietitian regarding dietary adherence and the development and reinforcement of strategies for continued success; although the diets were individualized to achieve a 500 kcal/person/day deficit, comparable advice was given to patients in both treatment groups and diets were monitored weekly. All subjects maintained complete diet diaries, and compliance was

assessed by weekly subject interview and review of the diet diary and product return (analogous to pill-counts). Physical activity and tobacco use was assessed using standard questionnaires and maintained at prestudy (baseline) levels throughout the study.

Body weight and waist circumference were measured weekly, with subjects wearing street clothes with no shoes, outerwear or accessories. Body fat was measured at the beginning of the study and at week 12 using dual-energy X-ray absorptiometry (DEXA); DEXA was also utilized to ascertain regional fat loss (abdominal fat vs other regions). Blood pressure and fasting levels of circulating insulin, glucose, glucose:insulin ratio (as a screening index of insulin sensitivity) and lipids (triglycerides, and total and HDL cholesterol) were measured at the same time points (baseline and week 12).

Subjects

A total of 38 otherwise healthy, obese adults ranging in age from 18 to 50 y were initially enrolled and 34 completed the study; there were no significant differences between completers and noncompleters for any parameter studied. All noncompleters left the study due to scheduling conflicts ($n=3$) or relocating out of state ($n=1$). Of the four subjects who did not complete the study, three were assigned to the control group and one to the yogurt group, leaving sample sizes of 16 and 18 in the control and yogurt groups, respectively. All subjects had an initial body mass index (BMI) of 30.0–39.9 kg/m², a low-calcium diet (500–600 mg/day, as determined by food frequency and diet history) at study entry, no more than 3 kg weight change over the preceding 12 weeks and no recent (12 week) changes in exercise frequency or intensity. Patients were excluded from participation if they required the use of oral antidiabetic agents or insulin; utilized obesity pharmacotherapeutic agents and/or herbal preparations intended for the management of obesity; utilized calcium supplements; reported adverse responses to dairy products; had a history of significant endocrine, hepatic or renal disease; were pregnant or lactating; or suffered any form of malabsorption syndrome. Baseline subject characteristics are summarized in Table 1. This research was approved from an ethical standpoint by the Institutional Review Board of the University of Tennessee; informed consent was obtained from all subjects and the research was conducted in accordance with the ethical standards outlined in the Helsinki Declaration.

Diets

Baseline dietary assessments (diet records) were conducted by the project dietitian during the 2-week lead-in period to provide an initial estimate of a maintenance level of caloric intake. This was refined by calculating energy needs using World Health Organization equations for calculation of basal

Table 1 Baseline patient characteristics

	Control	Yogurt
Gender	14F, 2M	13F, 5M
Age (y)	42±6	39±10
BMI (kg/m ²)	33.2±0.9	32.1±0.4
Systolic blood pressure (mmHg)	123±11	124±11
Diastolic blood pressure (mmHg)	82±8	82±8
LDL cholesterol (mg/dl)	159±25	158±21
HDL cholesterol (mg/dl)	45±12	46±11
Triglycerides (mg/dl)	136±25	121±22

Table 2 Diet characteristics

	Control	Yogurt
Calcium intake (mg/day)	495±28	1077±22
Energy intake (kcal/day)	1303±190	1437±190
% Energy from fat	30±3	30±4
% Energy from protein	18±3	18±2
% Energy from carbohydrate	52±6	52±5

metabolic rate (BMR), which were then adjusted for activity level to provide an estimate of total daily energy expenditure (TDEE). TDEE was estimated as $1.3 \times$ BMR for obese patients engaged in mild daily activity and $1.5 \times$ BMR for those engaged in strenuous daily activity. Discrepancies between estimated TDEE and baseline caloric intake were resolved, if necessary, by repeat diet records reviewed by the project dietitian. Based on this initial estimate of caloric needs, a food exchange-based diet was prescribed to produce a caloric deficit of ~ 500 kcal/day. The diets for the treatment arms were constructed to provide comparable levels of macronutrient and fiber, to approximate the average consumption in the US (fat $\sim 35\%$ of total kilocalories, carbohydrates $\sim 49\%$, \sim protein 16%, fiber 8–12 g/day). Nutritional supplements were not permitted, and caffeine intake was maintained at a constant level (individualized for each patient, based on baseline assessment). Diets were prescribed and monitored as noted above, and the key characteristics of diets achieved by subjects are shown in Table 2.

Assessment

Body weight was measured with a calibrated scale and height measured with a wall-mounted stadiometer with subjects in street clothes with no outerwear or shoes. BMI was calculated via standard equation (kg/m²). Waist circumference was measured in the standing position, with measurements obtained midway between the lateral lower rib margin and the iliac crest. The measurements were taken mid-exhalation, and the average of two readings was recorded.

Total fat mass and percent lean and fat mass were assessed via DEXA (Lunar Prodigy) at baseline and at week 12 of study. The instrument was calibrated and a phantom was

assessed daily to determine if any drift had occurred; spine phantom variation was less than 1.8% throughout the study.

Blood pressure and heart rate measurements were taken with the subject seated in an upright position in a chair for at least 5 min with the arm supported at heart level. Blood pressure was measured with an appropriately sized cuff using a standard, calibrated sphygmomanometer on the same arm for every measurement. Two readings, at least 1 min apart, were taken and the average value reported.

Plasma glucose was determined using a glucose oxidase method and insulin via standard radioimmunoassay using commercially available kits (Linco Research Inc., St Charles, MO, USA). Fasting lipid profiles (cholesterol, LDL cholesterol, HDL cholesterol and triglyceride) were assessed using standard clinical techniques. Circulating glycerol¹⁷ was assessed at weeks 0 and 12 as an index of whole-body lipolysis.

Statistics

Data were assessed via multivariate MANOVA using SAS-PC software to facilitate evaluation of both the repeated-measures and independent group comparisons inherent to this study design. Only subjects who completed the entire study ($n=34$) were included in the data analysis. All data are presented as mean \pm s.e.m.

Results

As expected from the experimental design, all participants lost body weight and body fat due to the daily energy deficit of 500 kcal/day. However, both weight and fat (via DEXA) loss were significantly increased by the yogurt diet compared to the control diet (Figure 1). Participants on the low-calcium control diet lost 4.99 ± 0.5 kg of body weight, while this was increased by 22% for those on the yogurt diet to 6.63 ± 0.6 kg ($P < 0.01$, Figure 1, top panel). Fat loss followed a similar trend, although there was a greater augmentation of fat loss compared to weight loss. Participants on the control diet lost 2.75 ± 0.73 kg fat, while those on the yogurt diet lost 4.43 ± 0.47 kg ($P < 0.005$, Figure 1, middle panel). The disparity between the extent of augmentation of weight loss (22%) vs fat loss (61%) by the yogurt diet may be attributable to the significant reduction in the loss of lean body mass during energy restriction in participants on the yogurt diet (-1351 ± 156 g) vs the control diet (-1968 ± 212 g) ($P < 0.05$, Figure 1, bottom panel).

Consistent with our previous observations, trunk fat loss was augmented by 81% on the yogurt vs control diet ($P < 0.001$, Figure 2), and this was reflected in a markedly greater reduction in waist circumference (-3.99 ± 0.48 vs -0.58 ± 1.04 cm, $P < 0.001$, Figure 3). Moreover, the fraction of fat lost from the trunk was higher on the yogurt diet vs control ($P < 0.005$). Participants on the yogurt diet exhibited a significant increase in circulating glycerol (22.3%,




Figure 1 Effects of dietary treatments on body weight composition. Body weight is shown in the top panel, body fat loss (as measured by DEXA) is shown in the middle panel and change in lean body mass (as measured by DEXA) is shown in the bottom panel.




Figure 2 Effects of dietary treatments on trunk fat loss.




Figure 3 Effects of dietary treatments on waist circumference.

$P<0.001$), indicating an increase in lipolysis in individuals on this diet, while there was no significant change in circulating glycerol in participants on the control diet (Figure 4).




Figure 4 Effects of dietary treatments on circulating glycerol levels. Change in glycerol (%) is calculated as the change from week 0 to week 12 divided by the original (week 0) value and multiplied by 100.




Figure 5 Effects of dietary treatments on systolic (top panel) and diastolic (bottom panel) blood pressure.

There were no significant effects of any of the diets on systolic pressure (Figure 5, top panel) or circulating lipids, while the patients on the yogurt diet exhibited a significant reduction in diastolic pressure ($P<0.01$, Figure 5, bottom panel), consistent with the modest blood pressure lowering effects of both weight loss and dairy ingestion anticipated in overweight, normotensive individuals.²

Discussion

Data from this study confirm and extend our previous observations that inclusion of dairy products, in this case three six-ounce servings of yogurt, in the daily diet markedly augments fat loss secondary to modest energy restriction and results in a selective increase in the loss of central adiposity. Indeed, these results are remarkably consistent with our previous clinical trial observations,¹¹ in which a dairy-rich diet augmented fat loss by 64%, comparable to the 61% augmentation observed in the present study, and increased the fraction of fat lost from the central region of the body from 19 to 66%, quite similar to the increase in loss of central adiposity in the present study however, due to the longer duration (24 vs 12 weeks) of the previous trial, total weight and fat loss were ~75% greater in the aforementioned trial.¹¹ Further, the significant increase in circulating

glycerol, indicative of increased lipolysis, is consistent with our previous observations of the antilipolytic effect of 1,25-dihydroxyvitamin D in human adipocytes and corresponding increases in lipolysis in animals fed high-calcium diets.^{1,4,5,9,10,18}

These data add to a growing body of observational and clinical observations that support a role for dietary calcium and dairy foods in controlling excess adiposity. Indeed, a number of recent observational studies have noted an inverse relationship between dietary and/or dairy intake and body fat in both younger and older women,^{19–21} African-American women,²¹ and children.^{22–24}

Evaluating the effects of intact food products, rather than supplements or pharmacological compounds, presents a unique set of problems in clinical trials. Ideally, clinical studies are conducted in a double blind fashion; however, when testing food products, it can be impossible to provide a metabolically inert yet indistinguishable product to use as a placebo. Hence, a control food product was utilized in lieu of a true placebo in this trial. In choosing the control product, a number of factors were considered. These are listed with comments in Table 3. In addition to the sugar-free gelatin snack, which was ultimately chosen, rice milk puddings, granola bars and a pill placebo control were considered. These were rejected on the basis of palatability, sensory characteristics and difficulty of blinding. The gelatin snack was chosen because of its similarity in eating usage (as snack or part of meal), sensory properties (fruit flavors, smooth texture and chilled product) and believability in a diet plan. The greatest concern in using the gelatin snack was that by providing an extremely low-energy density control product, satiety might be induced on fewer calories, resulting in greater weight loss in the control group than would be expected. Although this increased the possibility of a Type I error, this was deemed acceptable.

Melanson *et al*²⁵ recently reported that calcium intake is positively correlated with whole-body fat oxidation measured in a whole-room calorimeter, with significant effects noted over a 24-h period, during sleep, and during light exercise. Davies *et al*²⁶ and Heaney *et al*^{6,27} have analyzed data from nine studies, including three controlled trials and six observational studies, of calcium intake in which body weight could be assessed as a secondary outcome. Overall, increased calcium intake was consistently associated with

reduced indices of adiposity (body weight, body fat and/or weight gain); the aggregate effect was each 300 mg increase in daily calcium intake associated with a 3 kg lower weight in adults and a 1 kg decrease in body fat in children.

Larger population studies similarly support relationship between dietary calcium, dairy and indices of adiposity. Epidemiological observations from NHANES I,²⁸ NHANES III,¹ The Quebec Family Study,¹² The Continuing Study of Food Intake by Individuals (CSFII¹³), the CARDIA (Coronary Artery Risk Development in Young Adults) study¹⁴ and the HERITAGE Family Study¹⁵ all support an inverse relationship between dietary calcium and/or dairy intake and body fat, BMI or obesity incidence. Moreover, Drapeau *et al*²⁹ recently reported a significant inverse relationship between changes in body fat and changes in fat-free and low-fat milk consumption in a 6-y follow-up of the Quebec Family Study. However, two recent reviews have pointed out the need for further direct clinical evidence for confirmation of this population-based evidence.^{30,31}

Notably, the inverse relationship between dietary calcium and obesity in the CARDIA study was explained solely by dairy intake and was not altered by adjustment for dietary calcium,¹⁴ indicating an additional effect of dairy beyond the mechanisms already cited for dietary calcium in modulating adiposity and obesity risk. This is consistent with our previous observations in rodent studies^{1,5,9,10} and clinical trial¹¹ demonstrating that dairy exerts a greater effect on adiposity than does an equivalent amount of calcium from supplemental or fortified sources. Although the mechanism for this additional effect is not clear, we have previously proposed that it may be attributable, in part, to additional dairy bioactive compounds, such as angiotensin converting enzyme inhibitors, which may act on the adipocyte renin-angiotensin system, as well as to the high concentration of branched-chain amino acids in dairy.^{3,4}

Our previous observations of a greater loss of central adiposity on dairy-rich diets in mice^{1,5} and clinical trial,¹¹ which are supported by results of the present study, have been perplexing. However, recent studies demonstrating a potential role for autocrine production of cortisol by adipose tissue in the generation of truncal obesity have prompted us to explore whether the increase in calcitriol, which occurs in response to low-calcium diets, might play a regulatory role in adipocyte cortisol production.

Table 3 Factors influencing choice of control food product

Relevant attribute	Comments
Eating occasion/time of eating	Control product eating occasions and frequency should match study product
Sensory characteristics	Similar organoleptic characteristics are desired—sweetness, temperature, texture, etc
Palatability	Should be similar to avoid compliance differences
Caloric content, macronutrients, energy density	Should match study product as closely as possible
Other (GI, insulin response, digestive system disturbances)	Differences in physiological responses that may affect weight loss should be minimized
No active ingredients	Avoid adding variables
Blind to subjects and investigators	Prevent bias

Human adipose tissue expresses significant 11- β -hydroxysteroid dehydrogenase-1 (11- β -HSD-1), which can generate active cortisol from cortisone, and visceral adipose tissue exhibits greater 11- β -HSD-1 expression than does subcutaneous adipose tissue.^{32,33} Further, selective overexpression of 11- β -HSD-1 in white adipose tissue of mice results in central obesity,^{34,35} while homozygous 11- β -HSD-1 knockout mice exhibit protection from features of the metabolic syndrome.³⁶ Preliminary data from this lab data demonstrate that calcium agonists, including calcitriol, exert rapid and substantial (3- to 6-fold) stimulation of cortisol production by human adipocytes,^{37,38} suggesting that the observed selective loss of central adiposity on high-calcium and high-dairy diets may be attributable, in part, to a reduction in cortisol production by visceral adipocytes. However, these preliminary data are at present only suggestive, as they are derived solely from *in vitro* studies. Nonetheless, they do provide a plausible mechanism for a heretofore inexplicable phenomenon.

In summary, isocaloric substitution of yogurt into the diet of obese adults results in a repartitioning of energy and body composition, resulting in reductions in body weight, total adiposity and central adiposity and an improved metabolic profile during energy restriction. *In vitro* data obtained in human adipocytes suggest that the partially selective effect on central adiposity may result, in part, from reductions in adipocyte cortisol production secondary to suppression of calcitriol levels on the higher calcium diets.

Acknowledgements

This research was supported by the Bell Institute of Health and Nutrition, General Mills Inc.

References

- Zemel MB, Shi H, Greer B, DiRienzo D, Zemel PC. Regulation of adiposity by dietary calcium. *FASEB J* 2000; **14**: 1132–1138.
- Zemel MB. Calcium modulation of hypertension and obesity: mechanisms and implications. *J Am Coll Nutr* 2001; **20**: 428S–435S.
- Zemel MB. Role of dietary calcium and dairy products in modulating adiposity. *Lipids* 2003; **38**: 139–146.
- Zemel MB. Role of calcium and dairy products in energy partitioning and weight management. *Am J Clin Nutr* 2004; **79**: 907S–912S.
- Shi H, DiRienzo D, Zemel MB. Effects of dietary calcium on adipocyte lipid metabolism and body weight regulation in energy-restricted aP2-agouti transgenic mice. *FASEB J* 2001; **15**: 291–293.
- Heaney RP. Normalizing calcium intake: projected population effects for body weight. *J Nutr* 2003; **133**: 268S–270S.
- Teegarden D. Calcium intake and reduction in weight or fat mass. *J Nutr* 2003; **133**: 249S–251S.
- Zemel B, Nocton AM, Richards J, Milstead A, Gebhardt L, Campbell PJ. Increasing dairy calcium intake reduces adiposity in obese African-American adults (abstract). *Circulation* 2002; **106** (Suppl 2): II-610.
- Zemel MB, Sun X, Geng X. Effects of a calcium-fortified breakfast cereal on adiposity in a transgenic mouse model of obesity (abstract). *FASEB J* 2001; **15**: A598.
- Zemel MB, Geng X. Dietary calcium and yogurt accelerate body fat loss secondary to caloric restriction in aP2-agouti transgenic mice (abstract). *Obes Res* 2001; **9**: 146S.
- Zemel MB, Thompson W, Milstead A, Morris K, Campbell P. Calcium and dairy acceleration of weight and fat loss during energy restriction in obese adults. *Obes Res* 2004; **12**: 582–590.
- Jacqmain M, Doucet E, Despres J-P, Bouchard C, Tremblay A. Calcium intake, body composition, and lipoprotein-lipid concentrations in adults. *Am J Clin Nutr* 2003; **77**: 1448–1452.
- Albertson AM, Good CK, Holschuh NM, Eldridge EL. The relationship between dietary calcium intake and body mass index in adult women: data from the Continuing Survey of Food Intake by Individuals, 1994–96 (abstract). *FASEB J* 2003; **17**: A289.
- Pereira MA, Jacobs DR, Van Horn L, Slattery ML, Kartashov AI, Ludwig DS. Dairy consumption, obesity, and the insulin resistance syndrome in young adults. The CARDIA study. *JAMA* 2002; **287**: 2081–2089.
- Loos R, Rankinen T, Leon A, Skinner JS, Wilmore JH, Rao DC, Bouchard C. Calcium intake is associated with adiposity in black and white men and white women of the HERITAGE family study. *J Nutr* 2004; **134**: 1772–1778.
- Shi H, Norman AW, Okamura WH, Sen A, Zemel MB. 1 α -25-Dihydroxyvitamin D₃ inhibits uncoupling protein 2 expression in human adipocytes. *FASEB J* 2002; **16**: 1808–1810.
- Boobis LH, Maughan RJ. A simple one-step enzymatic fluorometric method for the determination of glycerol in 20 μ L of plasma. *Clin Chim Acta* 1983; **132**: 173–179.
- Xue B, Greenberg AG, Kraemer FB, Zemel MB. Mechanism of intracellular calcium inhibition of lipolysis in human adipocytes. *FASEB J* 2001; **15**: 2527–2529.
- Lin YC, Lyle RM, McCabe LD, McCabe GP, Weaver CM, Teegarden D. Dairy calcium is related to changes in body composition during a two-year exercise intervention in young women. *J Am Coll Nutr* 2000; **19**: 754–760.
- Lovejoy JC, Champagne CM, Smith SR, deJonge L, Xie H. Ethnic differences in dietary intakes, physical activity, and energy expenditure in middle-aged, premenopausal women: the Healthy Transitions study. *Am J Clin Nutr* 2001; **74**: 90–95.
- Buchowski MS, Semanya J, Johnson AO. Dietary calcium intake in lactose maldigesting intolerant and tolerant African-American women. *J Am Coll Nutr* 2002; **21**: 47–54.
- Tanasescu M, Ferris AM, Himmelgreen DA, Rodriguez, Perez-Escamilla R. Biobehavioral factors are associated with obesity in Puerto Rican children. *J Nutr* 2000; **130**: 1734–1742.
- Carruth BR, Skinner JD. The role of dietary calcium and other nutrients in moderating body fat in preschool children. *Int J Obes Relat Metab Disord* 2001; **25**: 559–566.
- Skinner JD, Bounds W, Carruth BR, Ziegler P. Longitudinal calcium intake is negatively related to children's body fat indexes. *JADA* 2003; **103**: 1626–1631.
- Melanson EL, Sharp TA, Schneider J, Donahoo WT, Grunwald GK, Hill JO. Relation between calcium intake and fat oxidation in adult humans. *Int J Obes* 2003; **27**: 196–203.
- Davies KM, Heaney RP, Recker RR, Lappe JM, Barger-Lux MJ, Rafferty K, Hinders S. Calcium intake and body weight. *J Clin Endocrinol Metabol* 2000; **85**: 4635–4638.
- Heaney RP, Davies KM, Barger-Lux MJ. Calcium and weight: clinical studies. *J Am Coll Nutr* 2002; **21**: 152S–155S.
- McCarron DA. Calcium and magnesium nutrition in human hypertension. *Ann Intern Med* 1983; **98**: 800–805.
- Drapeau V, Despres J-P, Bouchard C, Allard L, Fournier G, Leblanc C, Tremblay A. Modifications in food-group consumption are related to long-term body weight changes. *Am J Clin Nutr* 2004; **80**: 29–37.
- Barr SI. Increased dairy product or calcium intake: is body weight or composition affected in humans? *J Nutr* 2003; **133**: 245S–248S.

- 31 Parikh S, Yanovski JA. Calcium intake and adiposity. *Am J Clin Nutr* 2003; **77**: 281–287.
- 32 Seckl JR, Walker BR. 11 β -Hydroxysteroid dehydrogenase Type 1—a tissue-specific amplifier of glucocorticoid action. *Endocrinology* 2001; **142**: 1371–1376.
- 33 Rask E, Olsson T, Soderberg S, Andrew R, Livingstone DE, Johnson O, Walker BR. Tissue-specific dysregulation of cortisol metabolism in human obesity. *J Clin Endocrinol Metabol* 2001; **86**: 1418–1421.
- 34 Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS. A transgenic model of visceral obesity and the metabolic syndrome. *Science* 2001; **294**: 2166–2170.
- 35 Masuzaki H, Yamamoto H, Kenyon CJ, Elmquist JK, Morton NM, Paterson JM, Shinyama H, Shart MGF, Fleming S, Mullins JJ, Seckl JR, Flier JS. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. *J Clin Invest* 2003; **112**: 83–90.
- 36 Kotelevstev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CR, Seckl JR, Mullins JJ. 11 β -Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia in obesity or stress. *Proc Natl Acad Sci USA* 1997; **94**: 14924–14929.
- 37 Zemel MB, Sobhani T. Intracellular calcium modulation of cortisol production in human adipocytes (abstract). *FASEB J* 2003; **17**: A323.
- 38 Morris KL, Miller SL, Zemel MB. Calcitriol regulation of 11- β hydroxysteroid dehydrogenase 1 (11- β -HSD1) and angiotensin II receptor 1 (AT1) expression in human adipocytes (abstract). *FASEB J* 18; **585**: 11.